The role of quinolones in abdominal surgery.
The quinolone antibiotics have been a major advance for the treatment of various types of infections. These agents have generally good safety profiles, broad-spectrum activity, and favorable pharmacokinetics. In addition, several of these antibiotics are available in both intravenous and oral formulations, which allows for sequential therapy resulting in potential cost savings. However, patients can develop serious central nervous system side effects (seizures) and phototoxicity. In addition, the bioavailability of agents in this class can be reduced by coadministration with cations, such as magnesium, aluminum, calcium, and iron, which may make bioavailability unpredictable in patients. Although older quinolones such as ciprofloxacin were effective as prophylactic agents for biliary procedures and colorectal surgery and for the treatment of intra-abdominal infections, the use of these older quinolones was limited by the development of resistant organisms. In addition, because these agents had poor activity against anaerobes such as Bacteroides fragilis, the agents had to be combined with an antianaerobic agent, such as metronidazole, when anaerobic coverage was required. Recently, a new quinolone, trovafloxacin, has become available. Trovafloxacin has demonstrated increased activity against anaerobes in animal and human studies. However, the clinical profile of trovafloxacin for abdominal infections has not been fully demonstrated, and there is some concern that its activity against aerobic gram-negative bacilli, especially Pseudomonas aeruginosa, may not equal that of ciprofloxacin. Moreover, the safety profile of trovafloxacin is disadvantageous owing to reports of severe hepatic toxicity.